{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:57:35Z","timestamp":1764194255059},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Oral propranolol has become first-line intervention for problematic infantile hemangioma (IH) that is not amenable to topical or intralesional therapies. Consensus data supporting its efficacy for other vascular anomalies does not exist. The purpose of this study was to determine the frequency and causes of propranolol use for vascular lesions other than IH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Referrals to our Vascular Anomalies Center between 2008 and 2017 were reviewed for patients treated with propranolol at an outside institution. Patient history, photographs, imaging studies, and\/or histopathology were evaluated by an interdisciplinary team to diagnose the vascular anomaly. Our center's diagnosis was compared to the referral diagnosis to categorize patients into 3 groups: Group 1 (patients were appropriately labeled with an IH); Group 2 (individuals were erroneously diagnosed with IH); and Group 3 (subjects were diagnosed with a vascular anomaly other than IH).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two hundred thirty-six patients met inclusion criteria. Group 1 (39%; n = 91) had an IH and were treated appropriately. Group 2 (20%; n = 49) was misdiagnosed with IH and incorrectly received propranolol. Group 3 (41%; n = 96) was given propranolol to treat another vascular anomaly. Propranolol did not have efficacy for vascular anomalies other than IH.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Propranolol commonly is used to treat lesions other than IH; misdiagnosis of a lesion as IH is a common cause. Propranolol should be used with caution to treat other types of vascular anomalies because patients are subjected to the risks of the drug without data supporting its efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/scs.0000000000004166","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T20:37:01Z","timestamp":1506717421000},"page":"2001-2003","source":"Crossref","is-referenced-by-count":9,"title":["Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma"],"prefix":"10.1097","volume":"28","author":[{"given":"Jeremy A.","family":"Goss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J.","family":"Konczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed H.","family":"Alomari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reid A.","family":"Maclellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arin K.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231107","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"Leaute-Labreze","year":"2008","journal-title":"N Engl J Med"},{"key":"R2-20231107","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PRS.0b013e3181f95b83","article-title":"Evaluation of terminology for vascular anomalies in current literature","volume":"127","author":"Hassanein","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"R3-20231107","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00006534-196701000-00010","article-title":"Induced resolution of cavernous hemangiomas following prednisolone therapy","volume":"39","author":"Zarem","year":"1967","journal-title":"Plast Reconstr Surg"},{"key":"R4-20231107","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199205283262203","article-title":"Interferon alfa-2a therapy for life-threatening hemangiomas of infancy","volume":"326","author":"Ezekowitz","year":"1992","journal-title":"N Engl J Med"},{"key":"R5-20231107","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MPH.0000000000000681","article-title":"Favorable response to sirolimus in a child with blue rubber bleb nevus syndrome in the gastrointestinal tract","volume":"39","author":"Unlusoy Aksu","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R6-20231107","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/pbc.24103","article-title":"Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach\u2013Merritt phenomenon","volume":"59","author":"Chiu","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R7-20231107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1525-1470.2012.01864.x","article-title":"Lack of effect of propranolol in the treatment of lymphangioma in two children","volume":"30","author":"Maruani","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"R8-20231107","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1620\/tjem.229.61","article-title":"Propranolol as an alternative treatment option for pediatric lymphatic malformation","volume":"229","author":"Ozeki","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R9-20231107","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/SCS.0000000000001265","article-title":"A propranolol nonresponsive mass: lymphangioma-mimicking hemangioma","volume":"26","author":"Gul","year":"2015","journal-title":"J Craniofac Surg"},{"key":"R10-20231107","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/pbc.24866","article-title":"Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol","volume":"61","author":"Akyuz","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20231107","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamaophthalmol.2013.2879","article-title":"Failure of systemic propranolol therapy for choroidal hemangioma of Sturge\u2013Weber syndrome: a report of 2 cases","volume":"131","author":"Krema","year":"2013","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal of Craniofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001665-201711000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T21:06:45Z","timestamp":1699391205000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001665-201711000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/scs.0000000000004166","relation":{},"ISSN":["1049-2275","1536-3732"],"issn-type":[{"value":"1049-2275","type":"print"},{"value":"1536-3732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}